Jyong Biotech Ltd. Ordinary Shares (MENS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN KYG831161065
Jyong Biotech Ltd. Ordinary Shares financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 USD | 0.00 USD |
| Gross profit | -120,000.00 USD | -100,000.00 USD |
| Operating income | -2.06 m USD | -2.61 m USD |
| EBIT | -1.98 m USD | -2.61 m USD |
| Net income | -3.02 m USD | -4.67 m USD |
| Diluted EPS – continuing operations | -0.04 USD | -0.06 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
More stocks
- Foghorn Therapeutics Inc. (FHTX)
- Lucara Diamond Corp (LUC.TO)
- MAXCYTE, INC. (MXCT)
- Compagnie Lebon S.A. (ALBON.PA)
- STLLR Gold Inc. (STLR.TO)
- WW INTERNATIONAL, INC. (WW)
- KLX Energy Services Holdings, Inc. (KLXE)
- Nykode Therapeutics ASA (NYKD.OL)
- K2 Gold Corporation (KTO.V)
- DEEP FISSION, INC. (FISN)
- Solux Co. Ltd (290690.KQ)
- B’IN Live Co Ltd (6625.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.